Variability of Creatine Metabolism Genes in Children with Autism Spectrum Disorder
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Creatine deficiency syndrome (CDS) comprises three separate enzyme deficiencies with overlapping clinical presentations: arginine:glycine amidinotransferase (GATM gene, glycine amidinotransferase), guanidinoacetate methyltransferase (GAMT gene), and creatine transporter deficiency (SLC6A8 gene, solute carrier family 6 member 8). CDS presents with developmental delays/regression, intellectual disability, speech and language impairment, autistic behaviour, epileptic seizures, treatment-refractory epilepsy, and extrapyramidal movement disorders; symptoms that are also evident in children with autism. The objective of the study was to test the hypothesis that genetic variability in creatine metabolism genes is associated with autism. We sequenced GATM, GAMT and SLC6A8 genes in 166 patients with autism (coding sequence, introns and adjacent untranslated regions). A total of 29, 16 and 25 variants were identified in each gene, respectively. Four variants were novel in GATM, and 5 in SLC6A8 (not present in the 1000 Genomes, Exome Sequencing Project (ESP) or Exome Aggregation Consortium (ExAC) databases). A single variant in each gene was identified as non-synonymous, and computationally predicted to be potentially damaging. Nine variants in GATM were shown to have a lower minor allele frequency (MAF) in the autism population than in the 1000 Genomes database, specifically in the East Asian population (Fisher’s exact test). Two variants also had lower MAFs in the European population. In summary, there were no apparent associations of variants in GAMT and SLC6A8 genes with autism. The data implying there could be a lower association of some specific GATM gene variants with autism is an observation that would need to be corroborated in a larger group of autism patients, and with sub-populations of Asian ethnicities. Overall, our findings suggest that the genetic variability of creatine synthesis/transport is unlikely to play a part in the pathogenesis of autism spectrum disorder (ASD) in children.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Low brain creatine content has been associated with muscle myopathies (e.g., weakness), voluntary or involuntary movement disorders that can affect muscle function and coordination, speech development, epilepsy, cognitive and motor development delays, and/or autism [53,61,203,204,206,207,208,209,210].”
From Creatine in health and disease (2021) · cites this paper as [209]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For this reason, high-dose, long-term creatine supplementation (e.g., 0.3–0.8 g/kg/day) throughout the lifespan is a nutritional strategy of increasing brain creatine content in these populations [53,61,203,204,206,207,208,209,210,211,212,213,214].”
From Creatine in health and disease (2021) · cites this paper as [209]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A method and server for predicting damaging missense mutations.
Adzhubei, I. A., Schmidt, S., Peshkin, L., Ramensky, V. E., Gerasimova, A., Bork, P., Kondrashov, A. S., & Sunyaev, S. R. (2010) · Nature Methods · doi:10.1038/nmeth0410-248 · Cited by 13,194 · cited 5×
“Computational software (SIFT [27], PolyPhen-2 [28] and MutationTaster [29]) all predict this variant to be damaging, and therefore pathogenic if homozygous (Table 1).”
MethodInfluentialLord, C., Risi, S., Lambrecht, L., Cook, E. H., Leventhal, B. L., DiLavore, P. C., Pickles, A., & Rutter, M. (2000) · Journal of Autism and Developmental Disorders · doi:10.1023/a:1005592401947 · Cited by 7,520 · cited 2×
“Participants received a diagnosis of ASD from clinician experts based on diagnostic and statistical manual of mental disorders, 4th edition (DSM-IV) criteria for ASD (autism, Asperger’s, or pervasive developmental disorder—not otherwise specified (PDD-NOS)) with the diagnosis confirmed by the autism diagnostic observa…”
MethodMutationTaster2: mutation prediction for the deep-sequencing age
Schwarz, J. M., Cooper, D. N., Schuelke, M., & Seelow, D. (2014) · Nature Methods · doi:10.1038/nmeth.2890 · Cited by 3,362 · cited 5×
“Computational software (SIFT [27], PolyPhen-2 [28] and MutationTaster [29]) all predict this variant to be damaging, and therefore pathogenic if homozygous (Table 1).”
MethodInfluentialToward objective classification of childhood autism: Childhood Autism Rating Scale (CARS)
Schopler, E., Reichler, R. J., DeVellis, R. F., & Daly, K. (1980) · Journal of Autism and Developmental Disorders · doi:10.1007/bf02408436 · Cited by 2,432 · cited 2×
“Children included from this subgroup also underwent assessment by clinician experts, however, rather than the ADOS, their assessment included observation with the Childhood Autism Rating Scale (CARS) [37] and the DSM-IV checklist.”
MethodPredicting Deleterious Amino Acid Substitutions
Ng, P. C., & Henikoff, S. (2001) · Genome Research · doi:10.1101/gr.176601 · Cited by 2,368 · cited 1×
“Computational software (SIFT [27], PolyPhen-2 [28] and MutationTaster [29]) all predict this variant to be damaging, and therefore pathogenic if homozygous (Table 1).”
MethodWallimann, T., Wyss, M., Brdiczka, D., Nicolay, K., & Eppenberger, H. M. (1992) · Biochemical Journal · doi:10.1042/bj2810021 · Cited by 2,011 · cited 1×
“This system acts as a temporal and spatial energy buffer, energy transducer and general regulator of cellular energetics [12].”
BackgroundMost genetic risk for autism resides with common variation
Gaugler, T., Klei, L., Sanders, S. J., Bodea, C. A., Goldberg, A. P., Lee, A. B., Mahajan, M., Manaa, D., Pawitan, Y., Reichert, J., et al. (2014) · Nature Genetics · doi:10.1038/ng.3039 · Cited by 1,239 · cited 1×
“It has been shown that single nucleotide polymorphisms (SNPs) can explain up to 40% of the variance in liability to ASD [6,7]; thus common genetic polymorphisms can be a major risk factor for autism.”
BackgroundLOVD v.2.0: the next generation in gene variant databases
Fokkema, I. F. A. C., Taschner, P. E. M., Schaafsma, G. C. P., Celli, J., Laros, J. F. J., & den Dunnen, J. T. (2011) · Human Mutation · doi:10.1002/humu.21438 · Cited by 1,048 · cited 2×
“However, the variant is listed in the Leiden Open Variation Database v2 [30] and is shown by one study to be benign.”
BackgroundCommon genetic variants, acting additively, are a major source of risk for autism
Klei, L., Sanders, S. J., Murtha, M. T., Hus, V., Lowe, J. K., Willsey, A. J., Moreno-De-Luca, D., Yu, T. W., Fombonne, E., Geschwind, D., et al. (2012) · Molecular Autism · doi:10.1186/2040-2392-3-9 · Cited by 418 · cited 1×
“It has been shown that single nucleotide polymorphisms (SNPs) can explain up to 40% of the variance in liability to ASD [6,7]; thus common genetic polymorphisms can be a major risk factor for autism.”
BackgroundCreatine deficiency in the brain: A new, treatable inborn error of metabolism
Stöckler, S., Holzbach, U., Hanefeld, F., Marquardt, I., Helms, G., Requart, M., Hänicke, W., & Frahm, J. (1994) · Pediatric Research · doi:10.1203/00006450-199409000-00023 · Cited by 417 · cited 1×
“concentration of these metabolites in blood [4,21,22].”
Rae, C., Digney, A. L., McEwan, S. R., & Bates, T. C. (2003) · Proceedings of the Royal Society of London. Series B: Biological Sciences · doi:10.1098/rspb.2003.2492 · Cited by 283 · cited 1×
“In two studies, creatine supplementation was convincingly shown to improve concentration [17], as well as short-term memory and learning [18] in healthy human subjects.”
Background(2013) · Handbook of Clinical Neurology · doi:10.1016/b978-0-444-59565-2.00053-8 · Cited by 251
Self-citationBrewer, G. J., & Wallimann, T. W. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0741968.x · Cited by 230
High Prevalence of SLC6A8 Deficiency in X-Linked Mental Retardation
Rosenberg, E. H., Almeida, L. S., Kleefstra, T., deGrauw, R. S., Yntema, H. G., Bahi, N., Moraine, C., Ropers, H.-H., Fryns, J.-P., deGrauw, T. J., et al. (2004) · The American Journal of Human Genetics · doi:10.1086/422102 · Cited by 213 · cited 1×
“1142 − 35G > A in intron 7, as well as several of the non-coding polymorphic variants [33].”
BackgroundEffects of creatine on mental fatigue and cerebral hemoglobin oxygenation
Watanabe, A., Kato, N., & Kato, T. (2002) · Neuroscience Research · doi:10.1016/s0168-0102(02)00007-x · Cited by 196 · cited 1×
“In two studies, creatine supplementation was convincingly shown to improve concentration [17], as well as short-term memory and learning [18] in healthy human subjects.”
BackgroundSchulze, A. (2003) · Molecular and Cellular Biochemistry · doi:10.1023/a:1022443503883 · Cited by 189 · cited 3×
“Treatment-refractory epilepsy and extrapyramidal movement disorders are exclusively seen in GAMT patients [4,8,10,23,24].”
BackgroundSelf-citationSchulze, A., Hess, T., Wevers, R., Mayatepek, E., Bachert, P., Marescau, B., Knopp, M. V., De Deyn, P. P., Bremer, H. J., & Rating, D. (1997) · The Journal of Pediatrics · doi:10.1016/s0022-3476(97)70075-1 · Cited by 170 · cited 1×
“concentration of these metabolites in blood [4,21,22].”
Self-citationPhenotype and genotype in 101 males with X-linked creatine transporter deficiency
van de Kamp, J. M., Betsalel, O. T., Mercimek-Mahmutoglu, S., Abulhoul, L., Grünewald, S., Anselm, I., Azzouz, H., Bratkovic, D., de Brouwer, A., Hamel, B., et al. (2013) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2013-101658 · Cited by 164
Self-citationGAMT deficiency: Features, treatment, and outcome in an inborn error of creatine synthesis
Mercimek-Mahmutoglu, S., Stoeckler-Ipsiroglu, S., Adami, A., Appleton, R., Araújo, H. C., Duran, M., Ensenauer, R., Fernandez-Alvarez, E., Garcia, P., Grolik, C., et al. (2006) · Neurology · doi:10.1212/01.wnl.0000234852.43688.bf · Cited by 158
Self-citationStockler-Ipsiroglu, S., van Karnebeek, C., Longo, N., Korenke, G. C., Mercimek-Mahmutoglu, S., Marquart, I., Barshop, B., Grolik, C., Schlune, A., Angle, B., et al. (2014) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2013.10.018 · Cited by 145 · cited 2×
“There is an even gender distribution in GAMT [10] and likely in AGAT deficiencies, whereas predominantly males are affected with the CrT defect.”
BackgroundSelf-citationClark, A. J., Rosenberg, E. H., Almeida, L. S., Wood, T. C., Jakobs, C., Stevenson, R. E., Schwartz, C. E., & Salomons, G. S. (2006) · Human Genetics · doi:10.1007/s00439-006-0162-9 · Cited by 144 · cited 1×
“813C > T, a synonymous variant in exon 5 [32], and c.”
BackgroundClinical characteristics and diagnostic clues in inborn errors of creatine metabolism
Stromberger, C., Bodamer, O. A., & Stöckler‐Ipsiroglu, S. (2003) · Journal of Inherited Metabolic Disease · doi:10.1023/a:1024453704800 · Cited by 130 · cited 1×
“CDS includes three separate deficiencies: arginine:glycine amidinotransferase (AGAT), guanidinoacetate methyltransferase (GAMT), and creatine transporter (CrT) [4,8,19].”
BackgroundExocytotic release of creatine in rat brain
Almeida, L. S., Salomons, G. S., Hogenboom, F., Jakobs, C., & Schoffelmeer, A. N. M. (2006) · Synapse · doi:10.1002/syn.20280 · Cited by 130 · cited 1×
“Creatine has been shown to act as a neuroprotective agent [13]; it protects rat hippocampal neurons against glutamate and amyloid beta peptide toxicity [14]; it seems to function as a potent natural survival and neuroprotective factor for γ-aminobutyric acid (GABA)-ergic neurons in a model for Huntington disease [15]…”
BackgroundManzi, B., Loizzo, A. L., Giana, G., & Curatolo, P. (2008) · Journal of Child Neurology · doi:10.1177/0883073807308698 · Cited by 118 · cited 1×
“Less than 5% of ASD cases can be attributed to routinely-screened-for inborn errors of metabolism [2,3].”
BackgroundBattini, R., Leuzzi, V., Carducci, C., Tosetti, M., Bianchi, M. C., Item, C. B., Stöckler‐Ipsiroglu, S., & Cioni, G. (2002) · Molecular Genetics and Metabolism · doi:10.1016/s1096-7192(02)00175-0 · Cited by 105 · cited 1×
“Mild seizures have been reported in only some of the cases [9,25,26].”
BackgroundInherited Metabolic Rare Disease
Pàmpols, T. (2010) · Advances in experimental medicine and biology · doi:10.1007/978-90-481-9485-8_23 · Cited by 88 · cited 1×
“Autism spectrum disorder (ASD) can be present in children with inborn errors of metabolism, the latter having a prevalence of 1 in every 800 live births [1].”
BackgroundAndres, R. H., Huber, A. W., Schlattner, U., Pérez-Bouza, A., Krebs, S. H., Seiler, R. W., Wallimann, T., & Widmer, H. R. (2005) · Neuroscience · doi:10.1016/j.neuroscience.2005.03.004 · Cited by 86 · cited 1×
“Creatine has been shown to act as a neuroprotective agent [13]; it protects rat hippocampal neurons against glutamate and amyloid beta peptide toxicity [14]; it seems to function as a potent natural survival and neuroprotective factor for γ-aminobutyric acid (GABA)-ergic neurons in a model for Huntington disease [15]…”
BackgroundInborn errors of creatine metabolism and epilepsy
Leuzzi, V., Mastrangelo, M., Battini, R., & Cioni, G. (2012) · Epilepsia · doi:10.1111/epi.12020 · Cited by 77 · cited 1×
“Mild seizures have been reported in only some of the cases [9,25,26].”
BackgroundAndres, R. H., Ducray, A. D., Huber, A. W., Pérez‐Bouza, A., Krebs, S. H., Schlattner, U., Seiler, R. W., Wallimann, T., & Widmer, H. R. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03337.x · Cited by 58 · cited 1×
“Creatine has been shown to act as a neuroprotective agent [13]; it protects rat hippocampal neurons against glutamate and amyloid beta peptide toxicity [14]; it seems to function as a potent natural survival and neuroprotective factor for γ-aminobutyric acid (GABA)-ergic neurons in a model for Huntington disease [15]…”
BackgroundShould Metabolic Diseases Be Systematically Screened in Nonsyndromic Autism Spectrum Disorders?
Schiff, M., Benoist, J., Aissaoui, S., Boespflug‐Tanguy, O., Mouren, M., de Baulny, H. O., & Delorme, R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021932 · Cited by 52 · cited 1×
“[34] screened urine from 203 children with non-syndromic autism and found none to be affected with CDS.”
BackgroundGuanidinoacetate methyltransferase deficiency (GAMT)
Gordon, N. (2009) · Brain and Development · doi:10.1016/j.braindev.2009.01.008 · Cited by 46 · cited 1×
“Treatment-refractory epilepsy and extrapyramidal movement disorders are exclusively seen in GAMT patients [4,8,10,23,24].”
BackgroundComeaux, M. S., Wang, J., Wang, G., Kleppe, S., Zhang, V. W., Schmitt, E. S., Craigen, W. J., Renaud, D. L., Sun, Q., & Wong, L. (2013) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2013.04.006 · Cited by 44 · cited 1×
“To date, there are 6, 29, and 88 pathogenic mutations described throughout the GATM, GAMT, and SLC6A8 genes, respectively [20].”
BackgroundNouioua, S., Cheillan, D., Zaouidi, S., Salomons, G. S., Amedjout, N., Kessaci, F., Boulahdour, N., Hamadouche, T., & Tazir, M. (2013) · Neuromuscular Disorders · doi:10.1016/j.nmd.2013.04.011 · Cited by 41 · cited 1×
“Mild seizures have been reported in only some of the cases [9,25,26].”
BackgroundClinical and Laboratory Data in a Sample of Greek Children with Autism Spectrum Disorders
Ververi, A., Vargiami, E., Papadopoulou, V., Tryfonas, D., & Zafeiriou, D. (2011) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-011-1414-7 · Cited by 41 · cited 1×
“Less than 5% of ASD cases can be attributed to routinely-screened-for inborn errors of metabolism [2,3].”
BackgroundPrevalence of Creatine Deficiency Syndromes in Children With Nonsyndromic Autism
Schulze, A., Bauman, M. L., Tsai, A. C., Reynolds, A., Roberts, W., Anagnostou, E. A., Cameron, J. M., Nozzolillo, A. A., Chen, S., Kyriakopoulou, L. G., et al. (2016) · PEDIATRICS · doi:10.1542/peds.2015-2672 · Cited by 31 · cited 4×
“Through this work, we have corroborated results determined in our prior prevalence study in which none of the 443 children with ASD was found to be affected with CDS [5].”
BackgroundResultInfluentialSelf-citationBetsalel, O. T., Rosenberg, E. H., Almeida, L. S., Kleefstra, T., Schwartz, C. E., Valayannopoulos, V., Abdul-Rahman, O. A., Poplawski, N. K., Vilarinho, L., Wolf, P., et al. (2010) · European Journal of Human Genetics · doi:10.1038/ejhg.2010.134 · Cited by 21 · cited 2×
“The variant was seen in 2/1900 patients with mental retardation [31].”
BackgroundScreening of Male Patients with Autism Spectrum Disorder for Creatine Transporter Deficiency
Newmeyer, A., deGrauw, T., Clark, J., Chuck, G., & Salomons, G. (2007) · Neuropediatrics · doi:10.1055/s-2008-1065353 · Cited by 16 · cited 1×
“The only other genetic screen was carried out by Newmeyer et al [35].”
BackgroundSchiff, M., Benoist, J., Aissaoui, S., Boespflug‐Tanguy, O., Mouren, M., de Baulny, H. O., & Delorme, R. (2011) · PLoS ONE · doi:10.1371/annotation/456e2365-a067-4063-b11b-6a2abeba3f20 · Cited by 14
Cited by
Creatine in health and disease
Kreider, R. B., & Stout, J. R. (2021) · Nutrients · doi:10.3390/nu13020447 · Cited by 227
Boktor, J. C., Adame, M. D., Rose, D. R., Schumann, C. M., Murray, K. D., Bauman, M. D., Careaga, M., Mazmanian, S. K., Ashwood, P., & Needham, B. D. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01752-y · Cited by 48
“S3C), and symptoms of severe creatine deficiency overlap with the behavioral features of ASD [126].”
BackgroundPark, G., Jeon, S. J., Ko, I. O., Park, J. H., Lee, K. C., Kim, M., Shin, C. Y., Kim, H., & Lee, Y. (2022) · Molecular Brain · doi:10.1186/s13041-022-00904-z · Cited by 42
The Autism Treatment Network: Bringing Best Practices to All Children With Autism
Coury, D. L., Murray, D. S., Fedele, A., Hess, T., Kelly, A. M., & Kuhlthau, K. A. (2020) · PEDIATRICS · doi:10.1542/2019-1895d · Cited by 25
Xiong, X., Liu, D., He, W., Sheng, X., Zhou, W., Xie, D., Liang, H., Zeng, T., Li, T., & Wang, Y. (2019) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2019.105594 · Cited by 21
Metadata
- Authors
- Cameron, J. M., Levandovskiy, V., Roberts, W., Anagnostou, E., Scherer, S., Loh, A., & Schulze, A.
- Affiliations
- Genetics and Genome Biology, Peter Gilgan Center for Research and Learning, Toronto, ON M5G 0A4, Canada
- University of Toronto (CA)
- Hospital for Sick Children (CA)
- Corresponding author
- Schulze, Andreas
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2017-07-31
- Volume
- 18
- Issue
- 8
- Pages
- 1665
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC5578055
- OpenAlex
- W2739593690
- Cited by
- 15
- References
- 38
- Citations by year
- 2025: 1 · 2024: 1 · 2023: 4 · 2022: 4 · 2021: 2 · 2020: 2 · 2019: 1
- FWCI
- 0.47
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- U.S. Department of Health and Human Services (UA3 MC11054)
- Autism Speaks (UA3 MC 11054)
- Health Resources and Services Administration (UA3 MC11054)
- Topics
- Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
- Keywords
- autism spectrum disorder, creatine deficiency syndrome, GATM, GAMT, SLC6A8, genetic variants, novel variants, minor allele frequency, genetic association, children
- MeSH terms
- Autism Spectrum Disorder, Amidinotransferases, Child, Child, Preschool, Creatinine, Female, Humans, Male, Nerve Tissue Proteins, Prospective Studies, Genetic Variation, Plasma Membrane Neurotransmitter Transport Proteins, Guanidinoacetate N-Methyltransferase
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.